GlassScriptPhysician profile
Asif Rahman
NPI 1003902370
$7,808.39
in general payments reported to CMS, 2019-2025
28 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,818 · 2020: $1,146 · 2021: $1,342 · 2022: $1,115 · 2023: $1,725 · 2024: $245 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.33 |
| Education | $148.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,256.80 | 2019-2023 | Farxiga |
| Amgen INC. | $1,101.73 | 2019-2023 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $1,054.72 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $852.30 | 2019-2023 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $355.79 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $288.41 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $281.97 | 2021-2023 | Jesduvroq, Benlysta |
| Arbor Pharmaceuticals, INC. | $270.72 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $238.66 | 2020-2023 | Terlivaz, Acthar |
| Alexion Pharmaceuticals, INC. | $237.11 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $235.65 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $219.62 | 2021-2023 | Lupkynis |
| Horizon Therapeutics Plc | $218.78 | 2019-2021 | |
| Nxstage Medical, INC. | $182.71 | 2019-2025 | Liberty Select Cycler, Nxstage System One, Nxstage Pureflow Solution |
| Bayer Healthcare Pharmaceuticals INC. | $141.54 | 2021-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $125.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.94 | 2023 | Jardiance |
| Pfizer INC. | $123.46 | 2019 | |
| Ardelyx, INC. | $114.02 | 2025 | Xphozah 30 Mg |
| Abbvie INC. | $98.18 | 2022 | |
| Opko Pharmaceuticals, LLC | $92.02 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $74.41 | 2020 | |
| Recordati_rare_diseases_inc. | $27.75 | 2021 | |
| Novo Nordisk INC | $23.94 | 2023 | Ozempic |
| Lilly USA, LLC | $23.32 | 2023 | Jardiance |
| Daiichi Sankyo INC. | $19.31 | 2021 | |
| Allergan, INC. | $12.91 | 2019 | |
| Strongbridge US INC. | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asif Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.